The global human growth hormone market is witnessing growth due to the presence of large pool of patients and technological advancements. The increasing compliance for human growth hormone drugs and massive unexplored market in the emerging economies, such as India and China are creating opportunities for the growth of the global human growth hormone market. The advanced research and development facilities, and new drug developments by the key players are propelling the demand for improved and cost effective human growth hormones; further fuelling the growth of the global growth hormone market.
The increasing usage and development of recombinant human growth hormone drugs; increasing adoption of growth hormone drugs, as anti-aging drug; and growing popularity of human growth hormone drugs, as performance enhancing drugs are the key trends in the global human growth hormone market. Human growth hormone is a peptide hormone, stimulating growth in children and adolescents, and is produced by the pituitary gland. It helps in the growth of bones and muscles by specific cellular differentiation. Apart from stimulating growth, the human growth hormone also regulates carbohydrate metabolism, protein metabolism and fat metabolism. Moreover, the usage of human growth hormone drugs in growth hormone deficient patient has shown significant positive results on the patient’s working capacity, mental alertness and memory. The over secretion of growth hormone leads to gigantism and its deficiency causes dwarfism. The human growth hormone drugs are developed and manufactured by recombinant DNA technology. Earlier, these drugs were mostly used as replacement therapy in pediatric and adult patients, having the deficiency of growth hormones. However, the technological advancements and increased research and development in growth hormone drugs, have resulted in the development of anti-aging drugs and performance enhancers.
Some of the factors driving the growth of the global human growth hormone market are increasing demand for human growth hormone drugs, increasing incidences of human growth hormone deficiency diseases, growing geriatric population, and technological advancements, such as recombinant DNA technology for the development of human growth hormone drugs. In addition, several major players are investing heavily and collaborating among each other for the research and development of human growth hormone drugs, which is fueling the growth of the global human growth hormone market. However, stringent regulatory approvals, high cost of treatment, and adverse effects associated with the usage of synthetic human growth hormones are some of the factors restraining the growth of the global human growth hormone market to some extent.
Geographically, North America leads the global human growth hormone market, due to increasing proportion of aged population, high incidences of turner syndrome, short bowel syndrome, human growth hormone deficiency and Noonan syndrome. Moreover, the high demand of human growth hormone drugs as performance enhancer and anti-aging drug in North America is driving the growth of the human growth hormone market in the region. Asia-Pacific is the fastest growing region in the global human growth hormone market, which is driven by increasing healthcare expenditures and high incidences of growth hormone deficiency disorders. Moreover, the human growth hormone market is growing due to increasing disposable income and large geriatric population in the emerging countries, such as India and China.
Some of the major players operating in the global human growth hormone market are Pfizer Inc., F. Hoffmann-La Roche AG, Novo Nordisk A/S, Merck KGaA, Eli Lilly and Company, Novartis AG, and Teva Pharmaceutical Industries Ltd.